繁體版 / 簡體版
 
ABOUT US
/ MILESTONE

MILESTONE

  • 2016

    ? FB825 completed Phase I clinical trial in USA
    Microbio and Oneness Biotech co-setup PIC/S GMP plant in Taiwan Nan-Zhou
    Fountain Biopharma’s “Animal Center” received AAALAC accreditation
    Established “Sun BioFund Inc.”

  • 2015

    MB-110 received IND approval from US FDA for Phase I clinical trial
    OB318 received IND approval from TFDA for Phase I clinical trial
    ON101 began clinical pharmacokinetic tests
    Fountain Biopharma Translational Biochemical Analysis Centre certified by TAF technology

  • 2014

    FB825 received IND approval from US FDA for Phase I clinical trial
    ON101 received IND approval from Taiwan MOHW for multi-centers clinical trial
    ON101 received IND approval from Hong Kong DOH for Phase III clinical trial
    OB318 received IND approval from US FDA for Phase I clinical trial
    Diamond Biofund Inc. managed the largest “Evergreen Fund” in Taiwan, managing assets of NTD 8 billion
    Diamond Biofund Inc. initiated investment into Synovel, Sinew Pharma and 3D Global Biotech Inc.
    Fountain Biopharma setup “Animal Center” for Drug Screening

  • 2013

    Herbiron received NDA from Taiwan Ministry of Health & Welfare
    MB-6 began Phase III clinical trial
    Established “Diamond Biofund Inc.”

  • 2012

    “Fountain Biopharma Co., Ltd.” Listed on Taiwan Stock Exchange (4159)
    Established “Diamond Bio Venture” with Fubon Investment and Ruentex, raised NTD 3 billion

  • 2011

    MS-20 received NDA from Taiwan Ministry of Health & Welfare
    Established collaboration with Academia Sinica to develop new antibody through glycan engineering

  • 2010

    Established “Fountain Biopharma Co., Ltd.”, development of monoclonal antibody and protein new drugs
    Established the world largest fully human monoclonal antibody library
    GAP Site expansion in GaoXiong for plectranthus amboinicus

  • 2009

    Oneness Biotech Co., Ltd. listed on Taiwan Stock Exchange (4743)

  • 2008

    Established “Oneness Biotech Co., Ltd.”, development of botanical new drugs
    ON101 received Phase II IND approval from US FDA, TFDA and began Phase II clinical trial
    Herbiron began Phase III clinical trial
    MB-6 received Phase II IND approval from US FDA, TFDA and began Phase II clinical trial

  • 2006

    Microbio Co., Ltd. listed on Taiwan Stock Exchange (4128)

  • 2005

    Established2nd “Long-Tan” GMP Manufacturing Plant

  • 2004

    Established “Microbio (Shanghai) Co., Ltd.”
    Awarded “The First Biotech R&D Center in Taiwan” from MOEA

  • 2001

    Established “Long-Tan” GMP Manufacturing Plant
    MS-20 began Phase III clinical trial

  • 2000

    Micobio Co., Ltd. Founded

  • 1997

    Established of Microbio R&D platform


陕西快乐十分中奖技巧 国庆节双色球彩票停售吗 新疆25选7开奖号码 心水论坛599 (★^O^★)MG呼噜噜爱上乡下APP下载 单机水果老虎机游戏 三肖一码中特 湖北快3开奖结果今天3 安徽25选5开奖信息 天龙扑克 彩票华东15选5开奖查询 (*^▽^*)MG船长的宝藏爆分技巧 广西新快3 彩票又可以网购了 (*^▽^*)MG狂欢节送彩金 (-^O^-)MG奥林帕斯山的传说游戏说明 (*^▽^*)MG幸运双星如何爆大奖